Early-stage HR-positive, HER2-negative breast cancer is treated with curative intent, typically involving surgery with or without radiotherapy or chemotherapy, followed by adjuvant endocrine therapy for 5-10 years [12]. Here, ERBB2 is linked to breast cancer.